Results 151 to 160 of about 958,637 (251)

JAK-Inhibitors – A Story of Success and Adverse Events

Rebekka Wlassits,1 Mathias Müller,2 Karl H Fenzl,1 Thomas Lamprecht,3 Ludwig Erlacher3 1Karl Landsteiner Institut für Autoimmunerkrankungen und Rheumatologie, Vienna, Austria; 2Department für Biomedizinische Wissenschaften, Institut für Tierzucht und ...
Wlassits R, Müller M, Fenzl KH, Erlacher L, Lamprecht T   +4 more
core  

Inhibition of dipeptidyl peptidase 7 impairs lysophagy in LLOMe‐treated HepG2 cells

FEBS Letters, EarlyView.
DPP7 inhibition delays ubiquitin‐dependent lysophagy by attenuating ubiquitin accumulation and the recruitment of SQSTM1 and LC3 to damaged lysosomes, resulting in delayed clearance of damaged lysosomes and impaired restoration of lysosomal homeostasis. Created using FigureLabs (Certificate ID: FL‐PUB‐20260922‐Z99XNX).
Na Yeon Park, Inho Kwon, Yong Hwan Kim, Ji‐Eun Bae, Joon Bum Kim, Seong Hyun Kim, Sungho Maeng, Doo Sin Jo, Dong‐Hyung Cho   +8 more
wiley   +1 more source

Unveiling the Potential of JAK Inhibitors in Inflammatory Bowel Disease

Background: Janus kinase (JAK) inhibitors represent a novel class of oral therapies showing efficacy in treating ulcerative colitis (UC) and Crohn’s disease (CD), challenging conventional treatment paradigms.
Samantha McCall, Andrew H. Tsoi, Jonathan P. Segal, Sheng Wei Lo, Shahed Kamal, Beverly Rodrigues   +5 more
core   +1 more source

JAK Inhibitors for Alopecia Areata: Approved Therapies, Efficacy, and Unanswered Questions. [PDF]

Drug Des Devel Ther
Wu ZX, Tang WZ, Xu HY, Chen TY, Lan ZH, Yang YH, Liu RN, Li MS, Chen HW, Liu TH, Wang YH.   +10 more
europepmc   +1 more source

The role of miR‐335‐5p in the redifferentiation of BRAF p.V600E thyroid cancers

Molecular Oncology, EarlyView.
The BRAF p.V600E mutation promotes thyroid cancer dedifferentiation and radioiodine resistance. Using a network approach, we identified miR‐335‐5p as a key regulator of BRAF‐mutated thyroid tumors. Restoring miR‐335‐5p increased thyroid‐specific gene expression and iodine uptake in cells and organoids.
Valeria Pecce, Simone Bini, Marialuisa Sponziello, Giorgio Grani, Giulia Fiscon, Paola Paci, Lorenzo Farina, Rosa Falcone, Valentina Maggisano, Sebastiano Filetti, Cosimo Durante, Antonella Verrienti   +11 more
wiley   +1 more source

JAK inhibitors and adverse cardiovascular events: Class effect or molecule-specific risk? [PDF]

Front Pharmacol
Radić M, Bečić T, Prižmić PŠ, Pavlović MR, Vučković M, Radić J, Borovac JA, Fajkić A, Belančić A.   +8 more
europepmc   +1 more source

Tumour–host interactions in Drosophila: mechanisms in the tumour micro‐ and macroenvironment

Molecular Oncology, EarlyView.
This review examines how tumour–host crosstalk takes place at multiple levels of biological organisation, from local cell competition and immune crosstalk to organism‐wide metabolic and physiological collapse. Here, we integrate findings from Drosophila melanogaster studies that reveal conserved mechanisms through which tumours hijack host systems to ...
José Teles‐Reis, Tor Erik Rusten
wiley   +1 more source

Dermatologic Toxicities Induced by JAK Inhibitors. [PDF]

Am J Clin Dermatol
Rapparini L, Starace M, Apalla Z, El Barch M, Delpuech A, Baali S, Sibaud V.   +6 more
europepmc   +1 more source

Circular RNA expression landscapes in myelodysplastic neoplasms: Associations with mutational signatures and disease progression

Molecular Oncology, EarlyView.
In this explorative study, the abundance of circular RNA molecules in bone marrow stem cells was found to be elevated in patients with high‐risk myelodysplastic neoplasms, and to be associated with an increased risk of progression to acute myeloid leukemia.
Eileen Wedge, Morten Tulstrup, Gabriele Todisco, Pedro Moura, Christophe Côme, Jakob Werner Hansen, Jakob Schmidt Jespersen, Balthasar Schlotmann, Maria Creignou, Mette Dahl, Claudia Schöllkopf, Klas Raaschou‐Jensen, Krister Wennerberg, Bo Porse, Joachim Weischenfeldt, Eva Hellström‐Lindberg, Lasse Sommer Kristensen, Kirsten Grønbæk   +17 more
wiley   +1 more source

JAK Inhibitors in Colchicine Resistant FMF Patients: A Case-Based Review. [PDF]

Mediterr J Rheumatol
Salehzadeh F, Molatefi R, Khoei FB.
europepmc   +1 more source